|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
1998-8-31
|
|
pubmed:abstractText |
The CD20 antigen is expressed on more than 90% of B-cell lymphomas. It is appealing for targeted therapy, because it does not shed or modulate. A chimeric monoclonal antibody more effectively mediates host effector functions and is itself less immunogenic than are murine antibodies.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:Bence-BrucklerII,
pubmed-author:CabanillasFF,
pubmed-author:CzuczmanM SMS,
pubmed-author:DallaireB KBK,
pubmed-author:Grillo-LópezA JAJ,
pubmed-author:HeymanM RMR,
pubmed-author:HoA DAD,
pubmed-author:JainVV,
pubmed-author:LevyRR,
pubmed-author:LindB BBB,
pubmed-author:ListerJJ,
pubmed-author:McLaughlinPP,
pubmed-author:ShenDD,
pubmed-author:WeyKK,
pubmed-author:WhiteC ACA,
pubmed-author:WilliamsM EME
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2825-33
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:9704735-Adult,
pubmed-meshheading:9704735-Aged,
pubmed-meshheading:9704735-Antibodies, Monoclonal,
pubmed-meshheading:9704735-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:9704735-Antigens, CD20,
pubmed-meshheading:9704735-Antineoplastic Agents,
pubmed-meshheading:9704735-Disease Progression,
pubmed-meshheading:9704735-Drug Administration Schedule,
pubmed-meshheading:9704735-Female,
pubmed-meshheading:9704735-Humans,
pubmed-meshheading:9704735-Lymphoma, B-Cell,
pubmed-meshheading:9704735-Lymphoma, Follicular,
pubmed-meshheading:9704735-Lymphoma, Non-Hodgkin,
pubmed-meshheading:9704735-Male,
pubmed-meshheading:9704735-Middle Aged,
pubmed-meshheading:9704735-Recurrence
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
|
|
pubmed:affiliation |
Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA. pmclaugh@notes.mdacc.tmc.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
